Cytoskeletal perturbation leads to platelet dysfunction and thrombocytopenia in variant forms of Glanzmann thrombasthenia

Haematologica

Volumn 101, Issue 1, 2016, Pages 46-56

  Bury, Loredana ^a   Falcinelli, Emanuela ^a   Chiasserini, Davide ^a   Springer, Timothy A ^b   Italiano, Joseph E ^b   Gresele, Paolo ^a  

^a UNIVERSITY OF PERUGIA   (Italy)

^b BOSTON CHILDREN S HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACTIN POLYMERIZATION; ARTICLE; BLEEDING DISORDER; BLOOD ANALYSIS; CELL ADHESION ASSAY; CELL FUNCTION; CONTROLLED STUDY; CYTOSKELETAL PERTURBATION; DISEASE ASSOCIATION; GENE; GENE EXPRESSION; GENE MUTATION; GENETIC ASSOCIATION; GENETIC TRANSFECTION; GLANZMANN DISEASE; HUMAN; HUMAN EXPERIMENT; IMMUNOPRECIPITATION; ITGA2B GENE; ITGB3 GENE; MASS SPECTROMETRY; MUTAGENESIS; PHENOTYPE; PROTEIN PHOSPHORYLATION; QUANTITATIVE ASSAY; THROMBOCYTE ACTIVATION; THROMBOCYTE DYSFUNCTION; THROMBOCYTOPENIA; WESTERN BLOTTING; ANIMAL; CHO CELL LINE; CRICETULUS; CYTOSKELETON; FEMALE; GENETICS; HAMSTER; MALE; METABOLISM; MUTATION; PATHOLOGY; THROMBOCYTE;

ALPHA2 INTEGRIN; BETA3 INTEGRIN; ITGA2B PROTEIN, HUMAN; ITGB3 PROTEIN, HUMAN;

ANIMALS; BLOOD PLATELETS; CHO CELLS; CRICETINAE; CRICETULUS; CYTOSKELETON; FEMALE; HUMANS; INTEGRIN ALPHA2; INTEGRIN BETA3; MALE; MUTATION; THROMBASTHENIA; THROMBOCYTOPENIA;

EID: 84952938421     PISSN: 03906078     EISSN: 15928721     Source Type: Journal    
DOI: 10.3324/haematol.2015.130849     Document Type: Article

References (48)

1. Kasirer-Friede A, Kahn ML, Shattil SJ. Platelet integrins and immunoreceptors. Immunol Rev. 2000;218:247-264.
2. Larson MK, Watson SP. Regulation of proplatelet formation and platelet release by integrin αIIβ3. Blood. 2006;108(5):1509-1514.
3. Bury L, Malara A, Gresele P, Balduini A. Outside-in signalling generated by a constitutively activated integrin αIIβ3 impairs proplatelet formation in human megakaryocytes. PLoS One. 2012;7(4):e34449.
4. Springer TA, Dustin ML. Integrin inside-out signaling and the immunological synapse. Curr Opin Cell Biol. 2012;24(1):107-115.
5. Shattil SJ, Kim C, Ginsberg MH. The final steps of integrin activation: the end game. Nature Rev. 2010;1(4):288-300.
6. Fox JE. Cytoskeletal proteins and platelet signaling. Thromb Haemost. 2001; 86(1):198-213.
7. Berrou E, Adam F, Lebret M, et al. Heterogeneity of platelet functional alterations in patients with filamin A mutations. Arterioscler Thromb Vasc Biol. 2013; 33(1):e11-18.
8. Canobbio I, Noris P, Pecci A, Balduini A, Balduini CL, Torti M. Altered cytoskeleton organization in platelets from patients with MYH9-related disease. J Thromb Haemost. 2005;3(5):1026-1035.
9. Nurden AT, Fiore M, Nurden P, Pillois X. Glanzmann thrombasthenia: a review of ITGA2B and ITGB3 defects with emphasis on variants, phenotypic variability, and mouse models. Blood. 2011;118(23):5996-6005.
10. Nurden AT, Pillois X, Fiore M, Heilig R, Nurden P. Glanzmann thrombasthenia-like syndromes associated with macrothrombocytopenias and mutations in the genes encoding the αIIβ3 integrin. Semin Thromb Hemost. 2011;37(6):698-706.
11. Gresele P, Falcinelli E, Giannini S, et al. Dominant inheritance of a novel integrin αIIβ3 mutation associated with a hereditary macrothrombocytopenia and platelet dysfunction in two Italian families. Haematologica. 2009;94(5):663-669.
12. Zhu J, Luo BH, Xiao T, Zhang C, Nishida N, Springer TA. Structure of a complete integrin ectodomain in a physiologic resting state and activation and deactivation by applied forces. Mol Cell. 2008;32(6):849-861.
13. Butta N, Arias-Salgado EG, González-Manchón C, et al. Disruption of the β3 663-687 disulfide bridge confers constitutive activity to β3 integrins. Blood. 2003;102 (7):2491-2497.
14. Mor-Cohen R, Rosenberg N, Landau M, Lahav J, Seligsohn U. Specific cysteines in β3 are involved in disulfide bond exchangedependent and-independent activation of αIIβ3. J Biol Chem. 2008; 283(28):19235-19244.
15. Mor-Cohen R, Rosenberg N, Einav Y, et al. Unique disulfide bonds in epidermal growth factor (EGF) domains of β3 affect structure and function of αIIβ3 integrins in different manner. J Biol Chem. 2012;287(12): 8879-8891.
16. Kashiwagi H, Kunishima S, Kiyomizu K, et al. Demonstration of novel gain-of-function mutations of αIIβ3: association with macrothrombocytopenia and Glanzmann thrombasthenia-like phenotype. Mol Genet Genomic Med. 2013;1(2):77-86.
17. Vanhoorelbeke K, De Meyer SF, Pareyn I, et al. The novel S527F mutation in the integrin β3 chain induces a high affinity αIIβ3 receptor by hindering adoption of the bent conformation. J Biol Chem. 2009;284(22): 14914-14920.
18. Ghevaert C, Salsmann A, Watkins NA, et al. A nonsynonymous SNP in the ITGB3 gene disrupts the conserved membrane-proximal cytoplasmic salt bridge in the αIIβ3 integrin and cosegregates dominantly with abnormal proplatelet formation and macrothrombocytopenia. Blood. 2008;111(7):3407-3414.
19. Jayo A, Conde I, Lastres P, et al. L718P mutation in the membrane-proximal cytoplasmic tail of β3 promotes abnormal αIIβ3 clustering and lipid microdomain coalescence, and associates with a thrombasthenia-like phenotype. Haematologica. 2010;95(7):1158-1166.
20. Edelheit O, Hanukoglu A, Hanukoglu I. Simple and efficient site-directed mutagenesis using two single-primer reactions in parallel to generate mutants for protein structure-function studies. BMC Biotechnol. 2009;9:61.
21. Yan B, Smith JW. Mechanism of integrin activation by disulfide bond reduction. Biochemistry. 2001;40(30):8861-8867.
22. Giannini S, Mezzasoma A, Guglielmini G, Rossi R, Falcinelli E, Gresele P. A new case of acquired Glanzmann's thrombasthenia: diagnostic value of flow cytometry. Cytometry B Clin Cytom. 2008;74(3):194-199.
23. Schober JM, Lam SC, Wencel-Drake JD. Effect of cellular and receptor activation on the extent of integrin αIIβ3 internalization. J Thromb Haemost. 2003;1(11):2404-2410.
24. Kieffer N, Fitzgerald LA, Wolf D, Cheresh DA, Phillips DR. Adhesive properties of the β3 integrins: comparison of GPIIb-IIIa and the vitronectin receptor individually expressed in human melanoma cells. J Cell Biol. 1991;113(2):451-461.
25. Flevaris P, Stojanovic A, Gong H, Chishti A, Welch E, Du X. A molecular switch that controls cell spreading and retraction. J Cell Biol. 2007;179(3):553-565.
26. Falcinelli E, Guglielmini G, Torti M, Gresele P. Intraplatelet signaling mechanisms of the priming effect of matrix metalloproteinase-2 on platelet aggregation. J Thromb Haemost. 2005;3(11):2526-2535.
27. Susta F, Chiasserini D, Fettucciari K, et al. Protein expression changes induced in murine peritoneal macrophages by group B Streptococcus. Proteomics. 2010;10(11): 2099-2112.
28. Tabb DL, Fernando CG, Chambers MC. MyriMatch: highly accurate tandem mass spectral peptide identification by multivariate hypergeometric analysis. J Proteome Res. 2007;6(2):654-661.
29. Ma ZQ, Dasari S, Chambers MC, et al. IDPicker 2.0: improved protein assembly with high discrimination peptide identification filtering. J Proteome Res. 2009;8(8): 3872-3881.
30. Momi S, Falcinelli E, Giannini S, et al. Loss of matrix metalloproteinase 2 in platelets reduces arterial thrombosis in vivo. J Exp Med. 2009;206(11):2365-2379.
31. Bubb MR, Senderowicz AM, Sausville EA, Duncan KL, Korn ED. Jasplakinolide, a cytotoxic natural product, induces actin polymerization and competitively inhibits the binding of phalloidin to F-actin. J Biol Chem. 1994;269(21):14869-14871.
32. Thon JN, Montalvo A, Patel-Hett S, et al. Cytoskeletal mechanics of proplatelet maturation and platelet release. J Cell Biol. 2010;191(4):861-874.
33. Thon JN, Macleod H, Begonja AJ, et al. Microtubule and cortical forces determine platelet size during vascular platelet production. Nat Commun. 2012;3:852.
34. Dong X, Mi LZ, Zhu J, et al. αvβ3 integrin crystal structures and their functional implications. Biochemistry. 2012;51(44):8814-8828.
35. Cramer ER, Savidge GF, Vainchenker W, et al. Alpha-granule pool of glycoprotein IIb-IIIa in normal and pathologic platelets and megakaryocytes. Blood. 1990;75(6):1220-1227.
36. Donald JE, Zhu H, Litvinov RI, DeGrado WF, Bennett JS. Identification of interacting hot spots in the β3 integrin stalk using comprehensive interface design. J Biol Chem. 2010;285(49):38658-38665.
37. Bennett JS, Zigmond S, Vilaire G, Cunningham ME, Bednar B. The platelet cytoskeleton regulates the affinity of the integrin αIIβ3 for fibrinogen. J Biol Chem. 1999;274(36):25301-25307.
38. Wencel-Drake JD, Boudignon-Proudhon C, Dieter MG, Criss AB, Parise LV. Internalization of bound fibrinogen modulates platelet aggregation. Blood. 1996;87(2): 602-612.
39. Hung WS, Huang CL, Fan JT, et al. The endocytic adaptor protein Disabled-2 is required for cellular uptake of fibrinogen. Biochim Biophys Acta. 2012;1823(10):1778-1788.
40. Hato T, Pampori N, Shattil SJ. Complementary roles for receptor clustering and conformational change in the adhesive and signaling functions of integrin αIIβ3. J Cell Biol. 1998;141(7):1685-1695.
41. Handagama P, Scarborough RM, Shuman MA, Bainton DF. Endocytosis of fibrinogen into megakaryocyte and platelet alpha-granules is mediated by alpha IIb beta 3 (glycoprotein IIb-IIIa). Blood. 1993;82(1):135-138.
42. Bearer EL, Prakash JM, Li Z. Actin dynamics in platelets. Int Rev Cytol. 2002;217:137-182.
43. Hartwig JH, Italiano JE Jr. Cytoskeletal mechanisms for platelet production. Blood Cells Mol Dis. 2006;36(2):99-103.
44. Chen Z, Shivdasani RA. Regulation of platelet biogenesis: insights from the May-Hegglin anomaly and other MYH9-related disorders. J Thromb Haemost. 2009;7 (Suppl 1):272-276.
45. Nurden P, Debili N, Coupry I, et al. Thrombocytopenia resulting from mutations in filamin A can be expressed as an isolated syndrome. Blood. 2011;118(22):5928-5937.
46. Kunishima S, Okuno Y, Yoshida K, et al. ACTN1 mutations cause congenital macrothrombocytopenia. Am J Hum Genet. 2013;92(3):431-438.
47. Thon JN, Italiano JE Jr. Does size matter in platelet production? Blood. 2012;120(8): 1552-1561.
48. Kunishima S, Kashiwagi H, Otsu M, et al. Heterozygous ITGA2B R995W mutation inducing constitutive activation of the αIIβ3 receptor affects proplatelet formation and causes congenital macrothrombocytopenia. Blood. 2011;117(20):5479-5484.